Alcohol and drug use in adults with severe mental illness
Compares daily life and hospital stays in adults with severe mental illness.
Plain-language title generated from the registry record
Registry title: The Effect of Comorbid Alcohol/Substance Use
Key facts
- Where
- Bolu, TürkiyeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with schizophrenia-spectrum or other psychotic disorders, or bipolar disorder, who have been followed at a community mental health center for at least 6 months.
- Age
- 18 to 65 years
- Sex
- All sexes can join
- Disease stage
- A diagnosis of schizophrenia spectrum disorder and other psychotic disorders, or bipolar disorder, according to DSM-5 criteria
- Earlier treatment
- Actively followed up at the center (TRSM) for at least 6 months
Main reasons for not taking part
- Organic brain damage
- Neurodevelopmental disorders such as intellectual disability
- Severe cognitive impairment that prevents adequate communication
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07692984, who can take part
Where in Türkiye
- Melisa BulutBolu, TürkiyeContact: Melisa Bulut, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Abant Izzet Baysal University
- Trial code
- NCT07692984
- Record updated
- 13 July 2026
- Original description
Study Design This study was designed as a comparative, cross-sectional case-control study examining the effect of comorbid alcohol and substance use disorder (ASUD) on clinical course and social inclusion among individuals with severe mental illness followed at a Community Mental Health Center (CMHC). The study did not involve any interventions.Read full original descriptionShow less
The Effect of Comorbid Alcohol/Substance Use on Social Inclusion and Clinical Outcome in Individuals With Severe Mental Illness Enrolled in a Community Mental Health Center: A Cross-Sectional Case-Control Study
Study Design This study was designed as a comparative, cross-sectional case-control study examining the effect of comorbid alcohol and substance use disorder (ASUD) on clinical course and social inclusion among individuals with severe mental illness followed at a Community Mental Health Center (CMHC). The study did not involve any interventions.
Aim The aim of this study is to examine the effect of comorbid alcohol and substance use on clinical course parameters-such as number of hospitalizations and medication dosages-and on social inclusion indicators-such as employment, social participation, and social adjustment-among individuals with severe mental illness followed at the CMHC, in comparison with a matched control group without substance use.
Research Questions
What are the rates of comorbid alcohol and substance use among patients with severe mental illness followed at the CMHC? What are the current addiction symptoms, number of hospitalizations, and employment rates among individuals with severe mental illness and comorbid ASUD? What is the level of continuity of CMHC engagement and social participation among individuals with severe mental illness and comorbid ASUD, and what factors influence it? How does the level of social inclusion among individuals with severe mental illness and comorbid ASUD compare with that of individuals without ASUD?
Hypotheses
H1: The average annual number of hospitalizations among individuals with a dual diagnosis (severe mental illness + ASUD) followed at the CMHC is significantly higher than among those without substance use.
H2: Among individuals with a dual diagnosis, the daily medication doses (e.g., chlorpromazine equivalents) required to control psychotic or manic symptoms are higher than in the control group.
H3: Social inclusion is lower among patients with substance use compared with the control group.
H4: Employment rates among individuals with a dual diagnosis are significantly lower than among those with severe mental illness alone.
H5: Substance use negatively affects patients' social participation, including involvement in activities and friendships.
H6: Attendance rates at CMHC workshops and rehabilitation programs are lower among individuals with substance use compared with the control group.
Inclusion: Being 18 years of age or older,; Having a diagnosis of Schizophrenia Spectrum Disorder and Other Psychotic Disorders or Bipolar Disorder according to DSM-5 diagnostic criteria,; Being actively followed up at the TRSM for at least 6 months.
Exclusion: Individuals diagnosed with organic brain damage or neurodevelopmental disorders (intellectual disability, etc.),; Individuals with severe cognitive impairment that prevents them from communicating adequately.